17-AAG induces in vitro apoptosis [29] and in vivo tumour growth retardation in OS as a single agent and in combination with cisplatin [187] and restores the efficacy of the IGF1R inhibitor and imatinib in EW models [186]. Here, IGF1R is linked to neoplasm.